Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
Fundamental analysis (3 videos)Picked by YouTube search, not by us. Other people's views, not advice.
What Could Alnylam Pharmaceuticals (ALNY) Five Year HELIOS B Data Change?Simply Wall St., 2h ago
Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026Business Wire, 14h ago
Oracle upgraded, Reddit downgraded: Wall Street's top analyst callsThe Fly, Nov 2
Should You Buy The Dip In Alnylam Stock?Trefis, Nov 2
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilienceBioPharma Dive, Nov 2
Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More24/7 Wall St., Nov 2Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
The figures behind themQuiet so far: sample voices, tagged Sample, fill in until 5 players have posted.
Down over three months for a reason. Fading this bounce.
Bounced hard off support yesterday. Riding the momentum one more day.
That P/E still feels rich to me for this kind of business.
Comps are bottoming. The turnaround finally shows up in the numbers next week.
Join the floor. Sign up free to post and vote. No money involved.Sign up free
Posts are players' opinions and aren't advice. Sample posts are made up to show how the floor works. Three reports hide a comment until a moderator looks.
Result
Day 2 of 5Long Fama and French, Dave Portnoy, Michael Steinhardt
Short Louis Bacon, Richard Dennis, Jesse Livermore
Each bot is modeled on an investor's published approach, not the investor.
The next stock drops at the 9:30 am ET open.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
From Yahoo Finance, alnylam.com
The next results date isn't out yet.
Read the latest report: 10-Q, filed Thu, Oct 29, 2026| Quarter ending | Sep 2026 | Jun 2026 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | $1.5B | $1.3B | $1.2B | $774M |
| Gross margin | 75.2% | 76.9% | 84.2% | 81.6% |
| Operating margin | 23.7% | 17.9% | 29.5% | -2.1% |
| Net margin | 148.6% | 12.7% | 23.4% | -9.3% |
| EPS, diluted | $15.72 | $1.21 | $2.14 | −$0.55 |
From the company's SEC filings, newest first.
Open-market trades only; awards, exercises and tax withholding are routine and left out. SEC Form 4. All Form 4s on EDGAR
Insider salePoint at a dot to read it.
Simple rules applied to its rank in the 100 and its open-market insider trades over the past year. Not investment advice.